465529-56-0

Basic information

• Product Name: 5-BROMO-2-METHYL-2H-INDAZOLE
• Synonyms: 5-BROMO-2-METHYL-2H-INDAZOLE;2H-INDAZOLE, 5-BROMO-2-METHYL-;5-BROMO-2-METHYLINDAZOLE;2-Methyl-5-bromoindazole;2-Methyl-5-bromo-2H-indazole
• CAS NO: 465529-56-0
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.061
• Product Categories: Indazole;Organohalides;Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Indazoles;New Products for Chemical Synthesis
• Mol File: 465529-56-0.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 322.677 °C at 760 mmHg
• Flash Point: 148.95 °C
• Appearance: /
• Density: 1.607g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.06±0.30(Predicted)
• CAS DataBase Reference: 5-BROMO-2-METHYL-2H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-METHYL-2H-INDAZOLE(465529-56-0)
• EPA Substance Registry System: 5-BROMO-2-METHYL-2H-INDAZOLE(465529-56-0)

Safety Data

• Hazardous Substances Data: 465529-56-0(Hazardous Substances Data)

Usage

General Description

5-BROMO-2-METHYL-2H-INDAZOLE is a chemical compound that belongs to the indazole class of organic compounds. It is a brominated derivative of 2-methyl-2H-indazole, which is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. 5-BROMO-2-METHYL-2H-INDAZOLE has applications in the production of dyes, pigments, and other organic materials, and it also has potential uses in the field of medicinal chemistry. Its structure and properties make it suitable for further chemical modifications and reactions to create new compounds with desired properties. This chemical has attracted attention from researchers and industry professionals for its potential as a versatile and valuable building block in organic synthesis and chemical manufacturing.

InChI:InChI=1/C8H7BrN2/c1-11-5-6-4-7(9)2-3-8(6)10-11/h2-5H,1H3

Upstream product

• 53857-57-1 5-bromo-1H-indazole 
• 74-88-4 methyl iodide 
• 465529-55-9 5-bromo-2H-indazole 
• 74-83-9 methyl bromide 
• 20357-20-4 5-bromo-2-nitrobenzaldehyde 
• 74-89-5 methylamine 
• 914311-53-8 5-bromo-2-fluoro-benzaldehyde O-methyl-oxime 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 40598-76-3 3,5-dibromoindazole 
• 40598-94-5 3-bromo-1H-indazole 
• 861796-22-7 acetic acid-(4-bromo-2-methyl-N-nitroso-anilide) 
• 24106-05-6 4'-bromo-2'-methylacetanilide 

Downstream Products

• 1189746-27-7 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole 
• 1823787-20-7 2‐(5‐bromo‐2‐methyl‐2H‐indazol‐3‐yl)propan‐2‐ol 
• 952319-71-0 (2-methyl-2H-indazol-5-yl)boronic acid 
• 1619903-55-7 N₁-[4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl]-N₄-(tetrahydro-2H-pyran-4-yl)cyclohexane-trans-1,4-diamine methanesulfonic acid salt 
• 1619903-54-6 trans‐N1‐{4‐[2‐methyl‐3‐(propan‐2‐yl)‐2H‐indazol‐5‐yl]pyrimidin‐2‐yl}‐N4‐(oxan‐4‐yl)cyclohexane‐1,4‐diamine 

Relevant articles and documents

Discovery of N-(4-(3-isopropyl-2-methyl-2 H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies

Hematologic malignancies (HM) start in blood forming tissue or in the cells of the immune system. Cyclin-dependent kinases (CDKs) regulate cell cycle progression, and some of them control cellular transcription. CDK inhibition can trigger apoptosis and could be particularly useful in hematological malignancies. Herein, we describe our efforts toward the discovery of a novel series of quinazoline derivatives as CDK inhibitors. Intensive structural modifications lead to the identification of compound 37d as the most active inhibitors of CDKs 1, 2, 4, 8 and 9 with balancing potency and selectivity against CDKs. Further biological studies revealed that compound 37d can arrest the cell cycle and induce apoptosis via activating PARP and caspase 3. More importantly, compound 37d showed good antitumor efficacy in multiple HM mice xenograft models with no obvious toxicity. These results indicated that CDK 1, 2, 4, 8, and 9 inhibitors could be potentially used to treat certain hematologic malignancies.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

CRYSTAL FORM, SALT TYPE OF SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR

A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.